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Abstract
 .Leukemia inhibitory factor LIF has become increasingly recognized as an important regulator of inflammation. This
study is designed to determine whether LIF has an effect on arachidonate metabolism in human airway epithelial cells. LIF
 . w3 x  .100 ngrml induced a significantly increased release of prelabeled H arachidonic acid AA from the human bronchial
 .epithelial cell line BEAS 2B cell as well as from the primary cultures of human bronchial epithelial cells. Exposure of the
 y5 . w3 xLIF stimulated BEAS 2B cells to calcium ionophore A23187 10 M, 15 min caused a further increase of H AA
 .release. To identify the role of cytosolic phospholipase A cPLA in this upregulation of AA release, further experiments2 2
were performed to determine the expression of cPLA in the BEAS 2B cells. Immunoblot analysis indicated that LIF2
increased cPLA protein expression. Ribonuclease protection assay showed that LIF induced an increase of cPLA mRNA2 2
levels following 3 h to 24 h treatment. Nuclear run-on experiments suggested that LIF upregulated cPLA gene expression2
through post-translational regulation. These results demonstrate that LIF induces cPLA gene expression and modulates2
arachidonate metabolism in airway epithelial cells.
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1. Introduction
 .Leukemia inhibitory factor LIF is a polyfunc-
tional cytokine of the nerve growth factor gene super-
w xfamily 1 . It has been reported to inhibit the prolifer-
ation and induce the differentiation of M1 murine
w xmonocytic leukemia cells 2 , stimulate the hepatic
w xacute phase protein synthesis 3 , induce changes in
w x w xlipid metabolism 4 , induce cachexia 5 , regulate
w xbone metabolism 6 , exert a protective effect against
Abbreviations: cPLA , phospholipase A ; LIF, leukemia in-2 2
hibitory factor; RPA, ribonuclease protection assay
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w xthe lethality of endotoxin 7 , stimulate myoblast
w xproliferation 8 , inhibit epithelial cell electrolyte
w x w xtransport 9 , activate eosinophils 10 , mediate blas-
w xtocyte implantation in the mouse uterus 11 , induce
w xneurotransmitter changes in transgenic mice 12 , and
w xenhance TNF-a induced oxygen tolerance 13 . LIF
can be produced in vitro by a variety of cells includ-
w x w xing mesenchymal cells 14 , synoviocytes 15 , chon-
w x w xdrocytes 16 , blastocytes 17 , monocytes
w xmacrophages 18 , endothelial cells, T-lymphocytes
w x w x19 , and thymic epithelial cells 20 . Lung fibroblasts
w xproduce LIF in response to IL-1, TGFb , or TNF 21 .
However, the physiological role of LIF in the airway
has not been fully explored.
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 .Phospholipase A s PLA s are esterases that hy-2 2
drolyze the sn-2 ester bonds in phosphoglyceride
molecules releasing a free fatty acid and a lysophos-
pholipid. These products may serve as intracellular
w xsecond messengers 22 and can be metabolized into
the potent inflammatory mediators, such as prosta-
glandins, leukotrienes, hydroxyeicosatetraenoic acids,
w xor platelet activating factor 23 . PLA s can be2
grouped into two major classes based on their molec-
w xular weight and cellular distribution 24,25 . The 14
kDa low molecular weight secretory form of PLA 2
 . 2qsPLA enzymes require millimolar levels of Ca2
for activity, are rich in intramolecular disulfide bonds,
 .consequently inactivated by dithiothreitol DTT , but
display no apparent selectivity for arachidonic acid
 .AA containing phospholipids. On the other hand,
the more recently described and cloned 85 kDa high
 . w xmolecular weight cytosolic PLA cPLA 26,272 2
has higher selectivity to hydrolyze phospholipids con-
taining AA esterified in the sn-2 position. The cPLA 2
has two functionally distinct domains, the Ca2q-inde-
pendent catalytic domain and the regulatory Ca2q-de-
pendent lipid binding domain which share homology
 .with protein kinase C PKC , Unc-13, synaptotagmin,
w xand rabphilin 28 . Like these proteins, cPLA 2
translocates from cytosol to cell membranes in the
presence of micromolar concentrations of Ca2q, where
it may interact with its substrates. A number of
agonists induce receptor mediated cPLA activation.2
It has been shown that activation of cPLA requires2
synergistic action of increased intracellular Ca2q and
w xcPLA phosphorylation 29–32 . While the N-termi-2
nal Ca2q-dependent lipid binding domain mediates
the translocation of cPLA from cytoplasm to mem-2
brane, the C-terminal region contains the phosphory-
w xlation site and the active catalytic site 33 .
Recently, it has been demonstrated that cPLA 2
activity is also regulated through modulation of its
gene expression. The cPLA enzyme is induced by2
 . w xinterleukin-l a IL-1a in fibroblasts 34 , by
 .macrophage colony stimulating factor M-CSF in
w x  .monocytes 35 , by tumor necrosis factor-a TNF-a
w x  .in HeLa cells 36 , by interferon-g IFNg in airway
w xepithelial cells 37 , and cross-linking of Fce-recep-
w xtors of mast cells 38 . The present study is designed
to understand the possible effect of LIF on cPLA 2
activity and gene expression in the airway epithelial
cells. We report that LIF increased PLA enzyme2
activity determined in intact cells and in an in vitro
activity assay. In addition, LIF increased cPLA pro-2
tein production and up-regulated the steady state
cPLA mRNA levels. These findings suggest that2
LIF may play an important role in the modulation of
airway epithelial cell eicosanoid generation.
2. Materials and methods
2.1. Cell culture
BEAS 2B cells, a human bronchial epithelial cell
line transformed by an adenovirus 12-SV40 virus
hybrid, were a gift from Dr. J.E. Lechner and Dr. C.
Harris, National Cancer Institute, National Institutes
w xof Health, Bethesda, Maryland 39 . The cells were
maintained in serum free, hormonally defined culture
 .media, LHC-8 Biofluids Inc., Rockville, MD and
2 grown on 175 cm tissue culture flasks FalconrBe-
.cton Dickinson, Oxnard, CA which were coated with
a thin layer of rat tail Type I collagen Collaborative
.Research, Bedford, MA . Experiments were per-
formed when the cells reached 80% confluence ap-
.proximately 30 million cellsrflask .
Normal human bronchialrtracheal epithelial cells
 .obtained from Clonetics, San Diego, CA were cul-
 .tured on 6 well 35-mm cell culture plates coated
with a thin layer of rat tail Type I collagen Col-
.laborative Research, Bedford, MA . The cells were
 .grown in BEGM media Clonetics, San Diego, CA .
Experiments were performed when the cells reached
 5 .80% confluence approximately 10 cellsrwell .
2.2. Arachidonic acid release
For the release of AA from the BEAS 2B cells,
cells grown on 175 cm2 culture flasks were labeled
wfor 18 h with 1 mCirml 5,6,8,9,11,12,14,15-
3 x w3 x . H arachidonic acid H AA 214 Cirmmol; Amer-
.sham Corp., Arlington Height, IL in LHC-8 media.
Following repeated washing with media, 20 ml of
fresh media were added to each flask. Subsequently,
some cultures were exposed to human recombinant
 . LIF 0.1–100 ngrml R and D systems, Minneapo-
.lis, MN , while others were maintained as controls.
Following 4–24 h incubation with LIF, the super-
natants were harvested for subsequent HPLC analy-
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sis. For the release of AA from the primary cultures
of normal human bronchialrtracheal epithelial cells,
the cells grown on 35-mm wells were labeled for 18
w3 xh with 1 mCirml H AA in BEGM media. Follow-
ing repeated washing with media, 2 ml of fresh media
were added to each well and the cells were stimulated
 .with LIF 100 ngrml for 12 h. The supernatants
collected from three separate wells were pooled as
one individual sample for further HPLC analysis. The
samples were extracted by octadecylsilane C18 car-
tridges Sep-Pak C18; Waters Associates, Milford,
.MA and chromatographed by reversed phase high
 .pressure liquid chromatography HPLC as previ-
w xously described 37 . Individual Sep-Pak C18 car-
tridges were prepared with 15 ml of methanol fol-
lowed by 5 ml of 5 mM ethylenediaminetetra-acetic
 .acid EDTA and 10 ml of water. Samples were
loaded onto the cartridges, washed with 10 ml of
water, and eluted with 4 ml of methanol. The
methanol fraction was collected, evaporated to dry-
ness under steady flow nitrogen gas and resuspended
 .in 200 ml of mobile phase A see below for analysis
by HPLC. An ultrasphere C18 Beckman Instru-
.  .ments, Fullerton, CA column 4.7 mm=250 mm
with 5 mm particle size was used. A gradient pro-
gram was used with mobile phase A, waterraceto-
 .nitrilerphosphoric acid 75:25:0.025 , and mobile
phase B, methanolracetonitrilertrifluoroacetic acid
 .60:40:0.0016 at a flow rate of 1.5 mlrmin. The AA
fraction of HPLC elution was collected and measured
for radioactivity.
The effect of calcium ionophore A23187 on
w3 xH AA release from LIF treated cells. The cells were
w xprelabeled with 3H AA and followed by treatment
 .with LIF 100 ngrml for 4–24 h as described above.
 .After washing the cells twice with HBSS y , the
cells were incubated with 10y5 M ionophore A23187
for 15 rain in HBSS containing 1.3 mM Ca2q. The
samples were processed as described above, and the
AA fraction of HPLC elution was collected and
measured for radioactivity.
2.3. Immunoblot of cPLA protein2
The BEAS 2B cells grown on 175 cm2 flasks were
 .incubated with LIF 100 ngrml . At the indicated
times, cells were rinsed twice and digested with 0.1%
collagenase for 10 min. After washing three times
with cold HBSS, the cells were resuspended in the
homogenization buffer 50 mM HEPES, pH 8.0, 1
mM EDTA, 1 mM EGTA, 100 mM leupeptin, 1 mM
w xdithiothreitol, 4 mM 4- 2-amineethyl benzene-
sulfonylfluoride, 10 mM phosphoramidon, 0.5 mM
soybean trypsin inhibitor, 15 mM aprotinin and 0.05%
.Triton X-100 . The cells were then sonicated on ice
for 4=15 seconds using a microprobe. The cell
lysate was obtained by centrifugation at 1000=g for
5 min to remove the nuclei, unbroken cells and
debris. Ten mg of the cell lysate protein was sub-
jected to SDS-PAGE on 8% polyacrylamide gels
using Tris glycine buffer. The separated proteins
were electrophoretically transferred onto a nitrocellu-
lose membrane, which was blocked with 10% non fat
milk overnight, then probed with a 1:1000 dilution of
rabbit anti-cPLA polyclonal antibody provided by2
.the Genetics Institute, Boston, MA and finally de-
tected with a 1:1000 dilution of horseradishperoxi-
dase-labeled protein A using the ECL Western Blot-
ting Detection system Amersham Corp., Arlington
.Height, IL . The cPLA protein levels were quanti-2
tated using a densitometer Molecular Dynamics,
.Sunnyvale, CA .
( )2.4. Immunoblot of LIF receptor LIFR protein
The expression of LIFR in BEAS 2B cells was
tested by immunoblotting using a 1:1000 dilution of
mouse anti-LIFR monoclonal antibody provided by
.Immunex, Seattle, WA . The BEAS 2B and Hela
cells were lysed by sonication in the homogenization
 .buffer without Triton X-100 as described above.
After initial centrifugation at 1000=g for 5 min to
remove the nuclei, unbroken cells and debris, the cell
lysate was further centrifuged at 100 000=g for 1 h
to produce a membrane pellet. The membrane pellet
was resuspended in the homogenization buffer con-
.taining 0.05% Triton X-100 . Ten mg of the isolated
membrane protein was used for immunoblotting as
described above.
( )2.5. Ribonuclease protection assay RPA
 .Cells were treated with LIF 100 ngrml for 3 to
24 h. Total cellular RNA was extracted from 175 cm2
culture flasks by the single step guanidinium thio-
cyanate–phenol–chloroform extraction method Tri
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.reagent, Molecular Research. Inc., Cincinnati, OH .
The RNA pellet was precipitated with isopropanol
and washed twice with 75% ethanol, and redissolved
in 100 ml DEPC water. To construct the probe for
cPLA mRNA, a 541 bp product of cPLA cDNA2 2
was amplified by PCR using the following primers: 5X
primer, 5X-ATGTCATTTATACATCCTTAC -
X  . X XCAGCACATT-3 1–30 ; 3 primer, 5 -TCCT-
X TCACTATTCTTTGCACCCAAGAGTTT-3 541–
.  .512 . The product of cPLA gene 1–541 was cloned2
into the TA cloning vector Invitrogen, San Diego,
.CA . Orientation of the insert was determined by
DNA sequencing using the dideoxynucleotide chain
termination method sequenase version 2; United
.States Biochemical, Cleveland, OH . The cPLA and2
 .glyceraldehyde 3-phosphate dehydrogenase GAPDH
RNA probe were prepared by in vitro transcription
using SP6 and T7 polymerase, respectively, with
w32 x P CTP. A RPA assay kit RPA 2; Ambion, Austin,
.TX was used for the following procedures. Hy-
bridization was performed at 458C for 16 h and with
 .  .10 mg for GAPDH or 20 mg for cPLA of total2
4  . 5  .RNA and 10 for GAPDH and 10 for cPLA 2
cpm of 32P-labeled RNA probe. After hybridization,
the unhybridized RNA was digested by addition of
1.25 Urml RNAse A and 50 Urml RNAse T1 and
incubated at 378C for 60 min. Digestion was termi-
nated by addition of RNase inactivation and precipi-
tation mixture. The protected RNA fragment was
analyzed by autoradiography after separation on 6%
polyacrylamider8 M urea gels. Both cPLA and2
GAPDH mRNA signals were found to increase in a
linear fashion under these experimental conditions.
2.6. Nuclear run-on assay
Nuclear run-on assays were performed as de-
w xscribed 37 . The BEAS 2B cells were stimulated
 .with LIF 100 ngrml for 30 min to 8 h and digested
 .with 0.1% collagenase in HBSS y for 10 min.
 .Following washing twice with cold HBSS y , the
cell pellet was resuspended in 4 ml NP40 lysis buffer
10 mM Tris-HCl pH 7.4, 10 mM NaCl, 3 mM
 .MgCl , 0.5% vrv Nonidet P-40, 50 mgrml leu-2
peptin, 1 mM dithiothreitol, 0.5 mM phenylmethyl-
.sulfonyl fluoride and 100 mgrml aprotinin , incu-
bated for 5 min on ice, and centrifuged at 500=g
for 5 min. The nuclear pellet was washed once with 4
ml NP40 lysis buffer and centrifuged at 500=g. The
supernatant was discarded, the nuclei were resus-
pended in 200 ml reaction buffer 10 mM Tris-HCl
pH 8.0, 5 mM MgCl , 300 mM KCl, 1 mM dithio-2
threitol, 0.5 mM each of ATP, CTP, and GTP and
w 32 x 200 mCi of a- P UTP 3000 Cirmmol, NEN,
.Boston, MA and reacted at 308C for 1 h. RNA was
extracted by guanidinium thiocyanate–phenol–chlo-
roform extraction method with the addition of 100
mg yeast carrier tRNA. The samples were resus-
pended to equal countsrminrml in hybridization
 7 .buffer 4=10 cpmrml containing 50 mM PIPES,
pH 6.8, 10 mM EDTA, 600 mM NaCl, 0.2% SDS,
and 100 mgrml denatured salmon testis DNA. Hy-
bridization to denatured cytosolic PLA and GAPDH2
plasmid DNAs slot blotted on nitrocellulose filters
was performed at 658C for 40 h following prehy-
bridization at 808C for 2 h in hybridization buffer
containing 1% SDS. After hybridization the filters
were washed in 2=SSC, 0.1% SDS for 1 h=2,
air-dried and exposed to X-ray film. For binding to
 .nitrocellulose, plasmids 4 mgrslot containing the
w x306 bp cPLA cDNA fragment 37 or the GAPDH2
cDNA were denatured by incubation with 0.2 N
NaOH for 30 min at room temperature. The DNA
was spotted onto nitrocellulose using the Schleicher
and Schuell slot blot apparatus.
2.7. LDH and DNA determination
LDH determinations were performed to assess for
the presence of cell toxicity LDH assay kit, Sigma
.Chemical Co., St. Louis, MO . DNA was quantitated
utilizing benzimidazole Hoechst 33258, Janssen
. w xChemica, Geel, Belgium 40 .
2.8. Materials
Ionophore A23187 and non radiolabeled AA were
purchased form Calbiochem, La Jolla, CA. Aprotinin,
leupeptin, AEBSF, phosphoramidon were purchased
from Boehringer Mannheim, Indianapolis, IN. Soy-
bean trypsin inhibitor was purchased from Biofluids
Inc., Rockville, MD. GAPDH template for RNA
probe was purchased from Ambion, Austin, TX.
Rainbow protein molecular weight markers were pur-
chased from Amersham, Arlington Heights, IL. All
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 .Fig. 1. Immunoblot of LIF receptor LIFR protein. The expres-
sion of LIFR in BEAS 2B cells was tested by immunoblotting
 .using an anti LIFR monoclonal antibody 1:1000 dilution . The
lysed cell supernatant of BEAS 2B cells and HeLa cells were
ultracentrifuged at 100000= g for 1 h to produce a cell mem-
brane pellet. The pellet was resuspended in homogenization
buffer and 10 mg of protein was used for immunoblotting. Each
lane represents the cells harvested from a different set of cell
cultures.
other chemicals were purchased from Sigma Chemi-
cal Co., St. Louis, MO.
2.9. Statistical analysis
Data are presented as mean"S.E.M. Statistical
analysis was performed by two sided Wilcoxon
signed-rank test except for the concentration-depen-
dent effect, which were analyzed by one way
ANOVA. P-0.05 was considered statistically sig-
nificant.
3. Results
3.1. The expression of LIFR in bronchial epithelial
cells
As LIFR is an essential component for an LIF-
specific effect, LIFR expression was studied in BEAS
2B cells and in HeLa cells which are known to
w xexpress LIFR 41 . The immunoblot demonstrates
that BEAS 2B cells express the 200 kDa LIFR
 .protein Fig. 1 .
[3 ]3.2. The effect of LIF on H AA release from the
BEAS 2B cells
The effect of LIF on cellular PLA activity was2
w3 xassessed by measuring the H AA release from the
BEAS 2B cells. Fig. 2A shows a representative HPLC
 .chromatogram of LIF 100 ngrml, 12 h induced
w3 xH AA release and Fig. 2B shows the effect of
w3 x  . w3 xFig. 2. The HPLC chromatogram of LIF induced H AA release A and ionophore A23187 induced H AA release from control and
 . 2 w3 xLIF treated BEAS 2B cells B . The cells grown on 175 cm culture flasks were labeled for 18 h with H AA in LHC-8 media.
Following repeated washing with media, 20 ml of fresh media were added to each flask. Subsequently, some cultures were exposed to
 .   ..   ..LIF 100 ngrml closed circle in A , while others were maintained as controls open square in A . Following 12 h incubation with
  ..   ..LIF, the supernatants were harvested. After washing, the cells were incubated with closed circle in B or without open square in B
10y5 M ionophore A23187 for 15 min in HBSS containing 1.3 mM Ca2q. The samples were chromatographed by HPLC and the AA
fraction was collected and measured for radioactivity. The values are the representative results of 8 separate experiments.
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A23187 stimulation of control and LIF 100 ngrml,
.12 h pre-treated cells. The peaks shown in the
figures correspond to the retention time of AA 59
.  .min fraction . LIF 100 ngrml induced a signifi-
w3 xcantly increased release of H AA following a 12–24
w3 xFig. 3. The effect of LIF on H AA release from BEAS 2B cells.
w3 xThe cells were prelabeled with H AA in LHC-8 media. Subse-
quently, some cultures were exposed to LIF, while others were
maintained as controls. Following 4–24 h incubation with LIF,
the supernatants were harvested. The samples were chromato-
graphed by HPLC and the AA fraction was collected and mea-
sured for radioactivity. A. The time-course effect of LIF 100
.ngrml treatment from 4–24 h and the results were expressed as
 ) .percentage of control ns6–8, P -0.05 . B. The dose-depen-
 .dent effect of LIF 0 to 100 ngrml incubated for 12 h. The
w3 x  .results were expressed as the amount of H AA released dpm
 .per flask ns4, P -0.05 .
w3 xFig. 4. The effect of LIF on H AA release from the primary
human bronchial epithelial cells. The primary cells were cultured
 .on the 6 well 35-mm plate coated with a thin layer of rat tail
w3 xType I collagen. The cells were prelabeled with H AA for 18 h
in BEGM media. Following repeated washing with media, 2 ml
of fresh media were added to each well. Subsequently, some
 .cultures were exposed to LIF 100 ngrml , while others were
maintained as controls. Following 12 h incubation with LIF, the
supernatants were harvested. The spent media collected from
three wells were pooled as one individual sample. The samples
were chromatographed by HPLC and the elutions were measured
for radioactivity. The values are the representative results of 4
separate experiments.
h incubation as compared to paired control cells Fig.
.3A, P-0.05, ns6–8 . The dose-dependent effect
w3 xof LIF on H AA release was tested at 12 h incuba-
tion. From control to 100 ngrml, LIF increased
w3 x H AA release in a dose-dependent manner Fig. 3B,
.P-0.05, ns4 . These results demonstrate that LIF
w3 xinduces prelabeled H AA release from the BEAS
2B cells. No evidence of LIF mediated toxicity at 24
h was evident by LDH determination as compared to
 .control cultures data not shown . In addition, no
differences in cell numbers were present between
control and LIF treated cultures as determined by
 .DNA quantitation data not shown .
3.3. The effect of calcium ionophore A23187 on
[3 ]H AA release from LIF treated cells
 .LIF 100 ngrml pre-treated and control BEAS 2B
cells were stimulated with the calcium ionophore
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 y5 . w3 xA23187 10 M for 15 min. The H AA release in
response to the subsequent ionophore A23187 stimu-
lation was significantly increased in LIF pre-treated
cells as compared to controls Fig. 2B, ns5–7,
.P-0.05 . No evidence of A23187 induced toxicity,
was evident by LDH determination as compared to
 .control cultures data not shown .
[3 ]3.4. The effect of LIF on H AA release in the
primary cultures of normal human bronchial r
tracheal epithelial cells
As LIF stimulated AA release from the BEAS 2B
human bronchial epithelial cell line, further experi-
ments were designed to study the effect of LIF on
cellular AA release from normal human airway ep-
ithelial cells. As shown in Fig. 4, LIF induced a
w3 xsignificantly increased release of prelabeled H AA
from the primary cultures of normal human
bronchialrtracheal epithelial cells.
3.5. The effect of LIF on the amount of cPLA2
protein
To identify the effect of LIF on cPLA protein2
levels, immunoblot of the supernatant prepared from
control and LIF treated cells was performed. While
LIF had no apparent effect on cPLA protein 1102
.kDa level after 4 h incubation, a 2.5 fold increase of
Fig. 5. The effect of LIF on the amount of cPLA protein. BEAS2
2 2B cells grown on 175 cm flasks were incubated with LIF 100
.ngrml for 4–24 h. At the indicated times, cells were harvested
and lysed as described in Section 2. 10 mg of protein from the
supernatant was subjected to immunoblotting. The cPLA pro-2
 .tein 110 kDa shown from the left as follows: treated with LIF
for 4, 12, 24 h and control. The data represents one of three
experiments with similar results. Densitometry was performed to
quantitate the cPLA protein level.2
Fig. 6. The effect of LIF on cPLA mRNA level in the BEAS 2B2
 .cells. The cells were treated with LIF 100 ngrml for 3, 8 and
24 h and total RNA was purified. 10 or 20 mg of the total RNA
were hybridized to GAPDH- and cPLA -specific radiolabeled2
RNA probes and assayed by RPA. The protected RNA fragments
 .  .of cPLA 541 bases and GAPDH 316 bases were visualized2
by autoradiography. The data represent one of three separate
experiments with similar results.
the cPLA protein was found after treatment with2
 .LIF for 12 and 24 h Fig. 5 .
3.6. The effect of LIF on cPLA2 mRNA le˝els
The steady state levels of cPLA2 mRNA in control
and LIF treated cells were analyzed by RPA. Fig. 6
 .shows the time course effect of LIF 100 ngrml on
cPLA mRNA levels. LIF induced a significant in-2
Fig. 7. The effect of LIF on cPLA gene transcription in the2
BEAS 2B cells. The BEAS 2B cells were treated with LIF 100
. 32ngrml for 30 min to 8 h. The nuclei were isolated and P-
labeled nuclear run-on products were hybridized to denatured
cPLA and GAPDH plasmid DNAs slot-blotted on nitrocellulose2
filters as described in Section 2. The filters were exposed to the
X-ray film for 2 days. The data shown are the representative of
four separate experiments.
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crease of cPLA mRNA accumulation following2
3–24 h treatment. These results suggest that LIF
increases the cPLA protein level by increasing2
cPLA mRNA expression.2
3.7. The effect of LIF on cPLA gene transcription in2
the BEAS 2B cells
To assay whether LIF stimulates cPLA gene2
transcription, the BEAS 2B cells were incubated with
 .LIF 100 ngrml for 30 min to 8 h and the isolated
nuclei analyzed by a nuclear ran-on assay as de-
scribed under Materials and Methods. As shown in
Fig. 7, LIF exhibited no effect on cPLA gene2
transcription. Thus, it is likely that LIF stimulates
cPLA mRNA and protein expression through a2
 .post-transcriptional regulatory mechanism s in air-
way epithelial cells.
4. Discussion
The current study demonstrates that LIF induces
the synthesis and prolonged activation of cPLA in2
 .human bronchial epithelial cells. LIF 100 ngrml
induced a significantly increased release of prela-
w3 xbeled H AA from the primary cultures of human
airway epithelial cells as well as from the BEAS 2B
human bronchial epithelial cell line. Immunoblot
analysis showed that LIF increased the amount cPLA 2
protein. Ribonuclease protection assay showed that
LIF increased cPLA mRNA level following 3–24 h2
treatment. Nuclear run on analysis suggested that LIF
increased the steady state level of cPLA mRNA2
through post-transcriptional regulation. The dose-de-
pendent effect of LIF on AA release and the exis-
tence of LIF receptor in the airway epithelial cells
demonstrated a specific effect of LIF. This study
demonstrates that LIF induces an at least 2-fold
increase in cPLA protein resulting in a coordinate2
increase in LIF induced AA release from the airway
epithelial cells.
LIF is thought to exert its effects in local environ-
ments. LIF is not normally detected in the murine or
w xhuman circulation 42 and intravenously injected LIF
is cleared extremely rapidly from the murine circula-
 . w xtion t s3–5 min 43 . LIF mRNA and protein is1r2
w xnot detected in extrauterine tissues 42,44,45 , but is
detectable in the lung, heart and liver in mice after
w xendotoxin administration 46 . LIF is not detected in
the circulation of patients with various inflammatory
diseases except for sepsis. However, elevated LIF
concentrations were detected in effusions associated
with pneumonia and peritonitis, in cerebrospinal fluid
from patients with bacterial meningitis, and in amni-
w xotic fluid from a woman with chorioamnioitis 47 .
Those observations show that LIF expression is under
tight control and that it may act primarily in a local
environment. The distribution of LIF receptors has
been investigated as well. Radioligand binding assays
reveal that specific and saturable binding of 125I-LIF
is observed in lung, liver and spleen homogenates
w x43 . Specific receptors for LIF are expressed on a
variety of cells known to respond to LIF, including
adipocytes, osteoblasts, neuronal cell lines, embry-
onal stem cells, embryonal carcinoma cells, hepato-
cytes, M1 monocytic leukemia cells, and activated
w xmacrophages 48 . The positive result of the im-
munoblot for LIFR, dose-dependent effect of LIF on
AA release and induction of cPLA gene expression2
by LIF in our study is the first report that shows
airway epithelial cells are capable of responding to
LIF. Since inflammatory cells such as monocytes,
macrophages, T-lymphocytes as well as structural
airway cells such as fibroblasts are known to produce
LIF, this cytokine might play a role in the regulation
of inflammatory events in the airway microenviron-
ment.
The availability of free arachidonic acid for further
metabolism depends on the generation of free arachi-
donic acid mostly by PLA and on the incorporation2
w xof free arachidonic acid into lysophospholipids 23 .
Free arachidonic acid generated by the cells may be
reesterified into lysophospholipids mainly by acyl-
CoA lysophosphatide acyltransferase or acyl-CoA
w xsynthase 23,49,50 . Therefore, the increase in the
w3 xH AA release after LIF stimulation from prelabeled
cells is the consequence of shifting the equilibrium of
release and incorporation of AA. Our results show
that LIF increased the expression of cPLA protein2
and it is likely that this effect contributes to the LIF
w xinduced 3H AA release from the cultured bronchial
w3 xepithelial cells. The H AA release in response to
the subsequent ionophore A23187 stimulation was
significantly increased in LIF pre-treated cells as
 .compared to controls Fig. 2B . This result suggests
( )T. Ikezono et al.rBiochimica et Biophysica Acta 1355 1997 121–130 129
that LIF treated cells possess activatable PLA activ-2
ity which is greater than in control cells.
The effect of LIF on cPLA gene transcription2
was assayed by nuclear run on analysis and the
results indicate that basal transcription rate of cPLA 2
gene was not significantly increased by LIF treat-
ment. Thus, the mechanism of LIF induced increase
in the steady state cPLA mRNA is likely due to the2
post-transcriptional regulation. The posttranscrip-
tional regulation of cPLA gene expression by LIF in2
airway epithelial cells is similar to the regulation of
w xcPLA by M-CSF in monocytes 35 .2
The airway epithelial cells have become increas-
ingly recognized for their ability to participate in the
regulation of local inflammatory and immune re-
sponses. Since cPLA is a key enzyme regulating the2
production of AA and lysophosholipid for subsequent
metabolism to potent lipid mediators of inflamma-
tion, LIF might have a important effect in the modu-
lation of airway inflammation.
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